Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 16/20 | 0.70 |
| ▸ | FLT3 | P36888 | 3/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.50 |
| ▸ | BLK | P51451 | 1/20 | 0.50 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.50 |
| ▸ | CCNH | P51946 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.49 |
| ▸ | JUN | P05412 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24606332 | 0.85 | IRAK4 (0.80) | IRAK4FLT3MAPK8MAPK9LCK | |
| SCHEMBL23683355 | 0.85 | IRAK4 (0.70) | IRAK4FLT3MAPK8MAPK9LCK | |
| SCHEMBL24828770 | 0.84 | IRAK4 (0.71) | IRAK4FLT3MAPK8MAPK9LCK | |
| SCHEMBL18427792 | 0.82 | IRAK4 (1.00) | IRAK4FLT3MAPK8LCKRET | |
| SCHEMBL19900082 | 0.80 | FLT3 (1.00) | IRAK4FLT3IRAK1 | |
| SCHEMBL26463492 | 0.79 | IRAK4 (0.77) | IRAK4FLT3MAPK8MAPK9MAPK10 | |
| SCHEMBL22145801 | 0.78 | IRAK4 (1.00) | IRAK4FLT3MAPK8LCKRET | |
| SCHEMBL25956952 | 0.77 | IRAK4 (0.69) | IRAK4FLT3LCKRETPDGFRB | |
| SCHEMBL22145804 | 0.77 | IRAK4 (1.00) | IRAK4FLT3LCKRETPDGFRB | |
| SCHEMBL24231865 | 0.75 | IRAK4 (0.56) | IRAK4FLT3MAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230144-A1 | IRAK DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230144-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK1, IRAK4 | IRAK4 3/4885FLT3 52/4885MAPK8 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.